touchIMMUNOLOGY joins Professor Philip Conaghan (University of Leeds, UK) at WCO21 to discuss improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis.
Questions
1. What is the rationale for the use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis? (00:13-01:15)
2. What reductions in the WOMAC scale are considered meaningful, and what is the clinical importance of these findings? (0:15-03:12)
3. Could you give us an overview of your pooled analysis of Phase 3 data and the improvement in the WOMAC subscales and physical function? (03:12-04:10)
4. Which patients are most likely to benefit from tanezumab and in whom is it contraindicated? (04:10-05:28)
Disclosures: Philip Conaghan is a consultant or a member of the speakers bureaus for AbbVie, AstraZeneca, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson
Filmed in coverage of the WCO21 Annual Meeting.
